Hong-Min Liu

Publications (2)5.26 Total impact

• Article: Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study.

  Chang-Ming Xiong, Xian-Ling Lu, Guang-Liang Shan, Bing-Xiang Wu, Xian-Yang Zhu, Guang-Hua Wu, Xiao-Feng Zeng, Tao Guo, Zhi-Hong Liu, Xin-Hai Ni, [......], Chun-De Bao, Shi-An Huang, Jian-Ying Chen, Wei-Feng Wu, Kai Huang, Chang-ling Li, Li-Hua Wang, Bei He, Jian-Guo He, Jian-Jun Li
  [show abstract] [hide abstract]
  ABSTRACT: The impact of sildenafil on pulmonary arterial hypertension (PAH) in Chinese patients has been less investigated. A prospective, open-label, uncontrolled and multicenter study, therefore, was carried out to address this issue. Ninety patients with multicause-induced PAH received oral sildenafil (75 mg/day) for 12 weeks. The 6-minute walk test (SMWT) and cardiac catheterization were performed at the beginning and the end of the 12 weeks. The primary endpoint was the changes in exercise capacity assessed by the SMWT; the secondary endpoint included assessment of functional class, evaluation of cardiopulmonary hemodynamics, and clinical worsening. Drug safety and tolerability were also examined. The results showed that there was a significant improvement in SMWT distances (342 ± 93 m vs 403 ± 88 m, P < .0001), Borg dyspnea score (2.9 ± 2.6 vs 2.4 ± 2.0, P = .0046), World Health Organization functional class, and cardiopulmonary hemodynamics (mean pulmonary artery pressure, P < .0001; cardiac index, P < .0001; pulmonary vascular resistance, P < .0001) after 12 weeks of oral sidenafil therapy. Almost all enrolled patients did not experience significant clinical worsening. This study confirms and extends the findings of previous studies relating to effects of sildenafil on PAH, suggesting that oral sildenafil is safe and effective for the treatment of adult patients with PAH in the Chinese population.
  The Journal of Clinical Pharmacology 03/2011; 52(3):425-31. · 2.91 Impact Factor
• Article: Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease.

  Xian-Ling Lu, Chang-Ming Xiong, Guang-Liang Shan, Xian-Yang Zhu, Bing-Xiang Wu, Guang-Hua Wu, Zhi-Hong Liu, Xin-Hai Ni, Xian-Sheng Cheng, Qing Gu, [......], Tao Guo, Hong-Min Liu, Wei-Jun Zhang, Hong Gu, Shi-An Huang, Jian-Ying Chen, Wei-Feng Wu, Kai Huang, Jian-Jun Li, Jian-Guo He
  [show abstract] [hide abstract]
  ABSTRACT: It has been demonstrated that sildenafil is effective in patients with pulmonary arterial hypertension (PAH). However, the impact of sildenafil on PAH in adults with congenital heart disease (CHD) has been less investigated. In this prospective, open-label, uncontrolled and multicenter study, 60 patients with PAH related to CHD received oral sildenafil (75 mg/day) for 12 weeks. The enrolled patients underwent six-minute walk test (SMWT) and cardiac catheterization at the beginning and the end of the 12 weeks. The primary end point was the changes in exercise capacity assessed by SMWT; the secondary end point included assessment of functional class, evaluation of cardiopulmonary hemodynamics, and clinical worsening (defined as death, transplantation, and rehospitalization for PAH). Drug safety and tolerability were also examined. Oral sidenafil significantly increased SMWT distances (422.94 ± 76.95 m vs. 371.99 ± 78.73 m, P < 0.0001). There was also remarkable improvement in Borg dyspnea score (2.1 ± 1.32 vs. 2.57 ± 1.42, P = 0.0307). Moreover, significant improvements in World Healthy Organization (WHO) functional class and cardiopulmonary hemodynamics were also discovered (mean pulmonary artery pressure, P = 0.0002; cardiac index, P < 0.0001; pulmonary vascular resistance, P < 0.0001). Side effects in this study were mild and consistent with reported studies. None of the enrolled patients experienced significant clinical worsening. This study confirmed and extended previous studies. It suggested that oral sildenafil was safe and effective for the treatment of adult patients with CHD-related PAH.
  Cardiovascular Therapeutics 12/2010; 28(6):350-5. · 2.35 Impact Factor